Modality
Nanobody
MOA
KRASG12Di
Target
PLK4
Pathway
Wnt
Endometrial CaGastric CaThymoma
Development Pipeline
Preclinical
~Feb 2022
→ ~May 2023
Phase 1
~Aug 2023
→ ~Nov 2024
Phase 2
Feb 2025
→ Feb 2026
Phase 2Current
NCT08921223
2,321 pts·Endometrial Ca
2025-02→2026-02·Active
2,321 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-02-042mo agoPh3 Readout· Endometrial Ca
Trial Timeline
Q2Q3Q42026
P2/3
Active
Catalysts
Ph3 Readout
2026-02-04 · 2mo ago
Endometrial Ca
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08921223 | Phase 2/3 | Endometrial Ca | Active | 2321 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Doxarasimod | Merck & Co | NDA/BLA | FGFR | |
| Zanusertib | AbbVie | Approved | PCSK9 | |
| Pexarelsin | AstraZeneca | Phase 1 | DLL3 | |
| Ivotuximab | GSK | NDA/BLA | GIP-R | |
| Bemanesiran | BioNTech | Phase 3 | PLK4 | |
| Peminaritide | Sarepta | NDA/BLA | PLK4 | |
| Pexaosocimab | United Therapeutics | NDA/BLA | PLK4 | |
| Polalucimab | Jazz Pharma | Preclinical | PLK4 | |
| ILM-2412 | Illumina | Phase 3 | PLK4 | |
| ROI-3353 | Roivant Sciences | Phase 1/2 | PLK4 |